Dabrafenib (GSK2118436)

Name: Dabrafenib (GSK2118436)
Brand: Selleck Chemicals
SKU: S2807
Rating: 5 (145 reviews)

For research use only.

Catalog No.S2807

145 publications

Dabrafenib (GSK2118436) Chemical Structure

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Selleck's Dabrafenib (GSK2118436) has been cited by 145 publications

Nature, 2019, 575(7781):203-209

PubMed: 31666698 ( click the link to review the publication )

Nat Med, 2018, 24(2):203-212

PubMed: 29334371 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Cancer Discov, 2018, 8(4):417-427

PubMed: 29431697 ( click the link to review the publication )

Nature, 2017, 550(7674):133-136

PubMed: 28953887 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2016, 352(6282):189-96

PubMed: 27124452 ( click the link to review the publication )

Nat Med, 2016, 22(9):1056-61

PubMed: 27500726 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Oncogene, 2020, 39(20):4132-4154

PubMed: 32238882 ( click the link to review the publication )

Cancers (Basel), 2020, 22;12(2) pii: E512

PubMed: 32098410 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Sci Rep, 2020, 8;10(1):7826

PubMed: 32385388 ( click the link to review the publication )

J Biol Chem, 2020, 295(8):2407-2420

PubMed: 31929109 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 13

PubMed: 32404982 ( click the link to review the publication )

Front Chem, 2020, 23;8:184

PubMed: 32266211 ( click the link to review the publication )

Anticancer Res, 2020, 40(4):1867-1874

PubMed: 32234874 ( click the link to review the publication )

Br J Cancer, 2020, 122(6):789-800

PubMed: 31932756 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):387-402

PubMed: 32142667 ( click the link to review the publication )

Mol Cell, 2019, 76(6):872-884

PubMed: 31606273 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2197

PubMed: 31097693 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5143

PubMed: 31723142 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )
Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0298-5

PubMed: 30742091 ( click the link to review the publication )

Eur J Cancer, 2019, 109:137-153

PubMed: 30721788 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):272

PubMed: 31227006 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):56

PubMed: 30728057 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31533235 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12824

PubMed: 31518489 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):128

PubMed: 31391125 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):119

PubMed: 31345255 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113616

PubMed: 31445021 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1225

PubMed: 30718660 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:223

PubMed: 31467489 ( click the link to review the publication )

Surgery, 2019, 10.1016/j.surg.2019.04.076

PubMed: 31585718 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Metabolites, 2019, 9(11)

PubMed: 31744229 ( click the link to review the publication )

Chembiochem, 2019, 10.1002/cbic.201900266

PubMed: 31152574 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0217399

PubMed: 31158244 ( click the link to review the publication )

Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520

PubMed: 31618797 ( click the link to review the publication )
Reprod Domest Anim, 2019, 54(5):741-749

PubMed: 30785650 ( click the link to review the publication )

Target Oncol, 2019, 14(5):619-626

PubMed: 31502118 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav8463

PubMed: 31453322 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

Ann Biomed Eng, 2019, 10.1007/s10439-019-02269-2

PubMed: 31020445 ( click the link to review the publication )

Sci Rep, 2019, 9(1):10865

PubMed: 31350469 ( click the link to review the publication )

Exp Gerontol, 2019, 126:110691

PubMed: 31421186 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31783660 ( click the link to review the publication )

Transl Oncol, 2019, 13(2):275-286

PubMed: 31874374 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Mol Cell, 2018, 69(6):923-937

PubMed: 29547721 ( click the link to review the publication )

Mol Cell, 2018, 70(5):920-935

PubMed: 29883609 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2500

PubMed: 29950559 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1466

PubMed: 29654229 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1090-1102

PubMed: 29196297 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(14):3377-3385

PubMed: 29650750 ( click the link to review the publication )

Cancer research, 2018, 78(2):542-557

PubMed: 29180473 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):84-95

PubMed: 29133617 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )
Mol Oncol, 2018, 12(1):74-88

PubMed: 29112787 ( click the link to review the publication )

Neoplasia, 2018, 20(5):467-477

PubMed: 29605720 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(22):3974-3985

PubMed: 30137437 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9991

PubMed: 29968772 ( click the link to review the publication )

Front Pharmacol, 2018, 9:856

PubMed: 30154717 ( click the link to review the publication )

ACS Med Chem Lett, 2018, 9(12):1199-1204

PubMed: 30613326 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36503-36514

PubMed: 30559933 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):325

PubMed: 29487283 ( click the link to review the publication )

Oncotarget, 2018, 9(17):13324-13336

PubMed: 29568360 ( click the link to review the publication )

Small GTPases, 2018, 10.1080/21541248.2018.1446697

PubMed: 29634387 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10724

PubMed: 30013176 ( click the link to review the publication )

NPJ Syst Biol Appl, 2018, 4:39

PubMed: 30416750 ( click the link to review the publication )

Oncoimmunology, 2018, 8(1):e1512456

PubMed: 30546949 ( click the link to review the publication )

Cell Syst, 2018, 7(2):161-179

PubMed: 30007540 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28294-28308

PubMed: 29983861 ( click the link to review the publication )

Neural Regen Res, 2018, 13(2):252-256

PubMed: 29557374 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4684-4696

PubMed: 28652244 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(19):3631-3645

PubMed: 28551825 ( click the link to review the publication )
Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15523

PubMed: 29138474 ( click the link to review the publication )

Anal Bioanal Chem, 2017, 409(15):3749-3756

PubMed: 28429064 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2741-2751

PubMed: 29048639 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68208-68220

PubMed: 28978109 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(11 Pt B):2980-2992

PubMed: 28408301 ( click the link to review the publication )

Cell Death Differ, 2017, 24(1):83-97

PubMed: 27834956 ( click the link to review the publication )

Genome Res, 2017, 27(4):613-625

PubMed: 28179366 ( click the link to review the publication )

Oncogene, 2017, 36(27):3842-3851

PubMed: 28263969 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28350298 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(29):E5930-E5939

PubMed: 28684402 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(10)

PubMed: 29064427 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )

Nat Commun, 2016, 7:10274

PubMed: 26817517 ( click the link to review the publication )

Autophagy, 2016, 12(10):1776-1790

PubMed: 27464255 ( click the link to review the publication )

Leukemia, 2016, 30(4):937-46

PubMed: 26582644 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

J Biol Chem, 2016, 291(34):17804-15

PubMed: 27226552 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(7):778-84

PubMed: 26810603 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0152104

PubMed: 27015094 ( click the link to review the publication )

Oncotarget, 2016, 8(35):58021-58036

PubMed: 28938534 ( click the link to review the publication )
Oncotarget, 2016, 7(21):30453-60

PubMed: 27028853 ( click the link to review the publication )

Sci Rep, 2016, 6:23713

PubMed: 27025703 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27557444 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75839-75853

PubMed: 27713119 ( click the link to review the publication )

Oncotarget, 2016, 7(12):15065-92

PubMed: 26918341 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.56

PubMed: 25952668 ( click the link to review the publication )

Mol Ther, 2015, 23(5):931-942

PubMed: 25619724 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(8):2021-2030

PubMed: 25748555 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Immunother, 2015, 38(1):12-23

PubMed: 25415284 ( click the link to review the publication )

Eur J Pharmacol, 2015, 762:283-92

PubMed: 26048310 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Cancer Res, 2015, 75(1):216-29

PubMed: 25381152 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(12):1934-7

PubMed: 26443648 ( click the link to review the publication )

Oncotarget, 2015, 6(38):40535-56

PubMed: 26497853 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(6):602-9

PubMed: 25795007 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )

J Clin Invest, 2014, 124(3):1406-17

PubMed: 24569374 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Transl Res, 2014, 164(5):411-23

PubMed: 25016932 ( click the link to review the publication )
The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Targets

B-Raf (V600E) ^[3] (Cell-free assay)	B-Raf ^[3] (Cell-free assay)	C-Raf ^[3] (Cell-free assay)
0.7 nM	5.2 nM	6.3 nM

In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-Raf^V600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-Raf^V600E. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
	MmizT4lv[XOnIFHzd4F6				MoHiTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFjpd{B1[WepZXSgRk1T[WZiVk[wNGUhdXW2YX70JIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiY3XscJMh[29vZYjwdoV{e2mwZzDDSGM{PyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBjcW:2aX75cIF1\WRvTVXLJJBzd3SnaX6gdIhwe3Cqb4L5cIF1cW:wIHL5JGFteGijU3Py[YVvKGG\|c3H5JJdqfGhiSVO1NEBw\iByLkCwNFch\|ryP	M3XablI1QTByNkez
SK-MEL-28	NWDkeWE6U2mwYYPlJGF{e2G7		MWCxJIg>		MYjJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCVSz3NSWwuOjhiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gSXJMKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFQh\|ryP	NEDGTY0zPDlyME[3Ny=>
HepG2	Mnn6T4lv[XOnIFHzd4F6				MYrJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCHUlugdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjByNDFOwG0>	M1PteFI1QTByNkez
COLO205	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MomzTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRMkC1JINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFch\|ryP	NYW3U4RPOjR7MEC2O\|M>
HepG2	NV\pUYZSTnWwY4Tpc44hSXO\|YYm=		NV\SPFNiPDVibXnu	NYXpZ2lQTE2VTx?=	NH7jeHRKdmirYnn0bY9vKG:oIFHsb\|UhcW5iVFfGMYJmfGFvc4TpcZVt[XSnZDDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCVbXHkNkBxcG:\|cHjvdplt[XSrb36geJJm[XSnZDDmc5IhPDVibXnud{BxemmxcjD0c{BVT0ZvYnX0ZUB{fGmvdXzheIlwdiCvZXHzeZJm\CCjZoTldkA3OCCvaX7zJIJ6KG:meYPz[Zkh[myxdDDzZ4FvdmW{IHHuZYx6e2m\|IIfpeIghUUN3MDDv[kA{NjdizszN	NX;Qe5VbOjR7MEC2O\|M>
HFF	MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUexNEDPxE1?	NGewZpM4OiCq	Mn;lSG1UVw>?	Mn;3TY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKGi3bXHuJGhHTiClZXzsd{Bp[XKkb4Lpcochf2muZDD0fZBmKEJvUnHmJJdqfGhiSVO1NEBw\iB\|IN88US=>	M3XSSlI{QDR2MEO4
SK-MEL-28	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NISyRWQyOCEQvF2=	NWnGS3Q{PzJiaB?=	NV[2UHpzTE2VTx?=	NEL2fJlKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdD3kdol3\W5iU1utUWVNNTJ6IHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yNEOg{txO	MofoNlM5PDRyM{i=
A375P-F11	NIHrOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnDWVlWOTBizszN	M1:3T\|czKGh?	M1e2ZmROW09?	NYr2XXJFUW6qaXLpeIlwdiCxZjDCMXJi\iCYNkCwSUBufXSjboSt[JJqfmWwIFGzO\|VRNUZzMTDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEexJO69VQ>?	MoeyNlM5PDRyM{i=
MALME-3M	NXzzdZZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHoT294OTBizszN	NXnQXWc5PzJiaB?=	M3q1PGROW09?	M4TFNGlEPTB;MTDuUS=>	NEfPTpozOzh2NECzPC=>
UACC-62	M{LWcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2C3eFExKM7:TR?=	NIDYT5Q4OiCq	NXK5c4c6TE2VTx?=	NUX4NHdNUUN3ME2xJI5O	NIq2PFkzOzh2NECzPC=>
C32TG	MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHr1Z2IyOCEQvF2=	NVTR[nF3PzJiaB?=	NYPBW2dxTE2VTx?=	MVfJR\|UxRTFibl2=	MV:yN\|g1PDB\|OB?=
SK-MEL-1	M4XrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjOZoxHOTBizszN	NHzBdHE4OiCq	MVHEUXNQ	M2XqcmlEPTB;MjDuUS=>	NG\TUFAzOzh2NECzPC=>
M14	MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXINVAh\|ryP	M1S2UFczKGh?	NIrmSpRFVVOR	MnLVTWM2OD1{IH7N	NGrzN4czOzh2NECzPC=>
SK-MEL-28	MmKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV2xNEDPxE1?	M4ewbFczKGh?	NFL4V3VFVVOR	NEK0U2lKSzVyPUOgcm0>	NXnF[YJpOjN6NESwN\|g>
A375	NWnj[FZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUK4OI9VOTBizszN	NFjVPZY4OiCq	MULEUXNQ	MUTJR\|UxRTRibl2=	NFHMTVAzOzh2NECzPC=>
DU-4475	NIiyVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYOxNEDPxE1?	MnvXO\|IhcA>?	NVzpPFVPTE2VTx?=	NUXm[pAyUUN3ME21JI5O	MWeyN\|g1PDB\|OB?=
UACC-257	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW[5[G1zOTBizszN	MnnJO\|IhcA>?	M1zsUWROW09?	NUTYNHI6UUN3ME22JI5O	NW\5T\|c5OjN6NESwN\|g>
Colo 205	NWXBPI9JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWOxNEDPxE1?	M{DvZlczKGh?	NHfsbFRFVVOR	NILzUpZKSzVyPUegcm0>	MWKyN\|g1PDB\|OB?=
SK-MEL-3	MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUmxNEDPxE1?	NHX5UGg4OiCq	MmjKSG1UVw>?	NHHxVpBKSzVyPUegcm0>	NWfVZmdnOjN6NESwN\|g>
SH-4	NIK3e\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1H0OlExKM7:TR?=	NILRSoE4OiCq	M1nPZWROW09?	MX\JR\|UxRThibl2=	NE\TPJkzOzh2NECzPC=>
A101D	MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDoZ4huOTBizszN	MYq3NkBp	M{nUdWROW09?	Mn;ZTWM2OD17IH7N	MmjjNlM5PDRyM{i=
ES-2	M3;qZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkT1NVAh\|ryP	NWrQeI9CPzJiaB?=	MonkSG1UVw>?	NHPNdplKSzVyPUWzJI5O	NIqwWYszOzh2NECzPC=>
HT-29	M2rUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnYPXBjOTBizszN	M3;DNFczKGh?	MX\EUXNQ	NEX4VIpKSzVyPU[2JI5O	NVf4eFZvOjN6NESwN\|g>
SW1417	MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWG4dnl5OTBizszN	MXi3NkBp	M3\y[GROW09?	NVq3ZnN2UUN3ME2xOVghdk1?	M1i2NVI{QDR2MEO4
SW872	NHezcllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVK1cXhVOTBizszN	NHOzRZc4OiCq	M1m3XWROW09?	NFvvOG5KSzVyPUO3O{BvVQ>?	NXywTmVYOjN6NESwN\|g>
RKO	NGGyTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjsNVAh\|ryP	MYq3NkBp	MWDEUXNQ	MXTJR\|UxRTJwNUKyJO69VQ>?	NH;sV2EzOzh2NECzPC=>
A673	M3vnd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrwNVAh\|ryP	NHP6coQ4OiCq	NEjKOVdFVVOR	M3rFNGlEPTB;MUCg{txO	MnrONlM5PDRyM{i=
GCT	M2TLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPVdo9yOTBizszN	M2T3bFczKGh?	MnXNSG1UVw>?	NXSzSVNWUUN3ME2xNEDPxE1?	MYSyN\|g1PDB\|OB?=
WM-115	M{HxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFywXooyOCEQvF2=	Mmr2O\|IhcA>?	M1\sUGROW09?	MVXJR\|UxRTVibl2=	MYeyN\|g1PDB\|OB?=
YUMAC	NGjNcVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnhXGxPOTBizszN	MXq3NkBp	NWL0ToNPTE2VTx?=	Mmn3TWM2OD13IH7N	MWSyN\|g1PDB\|OB?=
OV-90	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXmRmgyOCEQvF2=	MYS3NkBp	NVHnfJRnTE2VTx?=	NInwdJVKSzVyPUK5JI5O	MUWyN\|g1PDB\|OB?=
NCI-H508	Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWCxNEDPxE1?	MWe3NkBp	MnfySG1UVw>?	MoPETWM2OD1zMDFOwG0>	Moi1NlM5PDRyM{i=
MDA-MB-231	MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW[xNEDPxE1?	MkDIO\|IhcA>?	MnLYSG1UVw>?	NFiwZYhKSzVyPUGwJO69VQ>?	MUmyN\|g1PDB\|OB?=
SW756	MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TDdFExKM7:TR?=	NVK3WXF{PzJiaB?=	MUDEUXNQ	NImycpRKSzVyPUGwJO69VQ>?	M4TQOlI{QDR2MEO4
SW-837	NFrPN4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XtPFExKM7:TR?=	NFW4U\|Q4OiCq	NInHfllFVVOR	NYD6fpI3UUN3ME2xNEDPxE1?	NIDodngzOzh2NECzPC=>
UMUC-3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jqO\|ExKM7:TR?=	M1v4PVczKGh?	MluySG1UVw>?	MnLiTWM2OD1zMDFOwG0>	MX[yN\|g1PDB\|OB?=
LS-174T	M4fzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzIWZMyOCEQvF2=	NW\3NpZzPzJiaB?=	MkT6SG1UVw>?	MVXJR\|UxRTFyIN88US=>	M4TE[FI{QDR2MEO4
A549	M2O2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HRb\|ExKM7:TR?=	NITUZZc4OiCq	M1PacmROW09?	MXfJR\|UxRTFyIN88US=>	MVeyN\|g1PDB\|OB?=
SHP-77	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1njTVExKM7:TR?=	M2\SR\|czKGh?	Mn\MSG1UVw>?	NFT1V\|RKSzVyPUGwJO69VQ>?	MV:yN\|g1PDB\|OB?=
SW480	NGrGfJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nBN\|ExKM7:TR?=	NFr5WYQ4OiCq	MXXEUXNQ	MUfJR\|UxRTFyIN88US=>	NEnrcIozOzh2NECzPC=>
DLD-1	NGHJfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUWxNEDPxE1?	NI\CN5c4OiCq	M1ntV2ROW09?	M1LqNWlEPTB;MUCg{txO	NELLXpEzOzh2NECzPC=>
HCT-116	NVywVJNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVyxXZpYOTBizszN	NVq2R4lWPzJiaB?=	MYfEUXNQ	NHnacIdKSzVyPUGwJO69VQ>?	Mn3HNlM5PDRyM{i=
NCI-H747	M1jod2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVGxNEDPxE1?	NFrrUo04OiCq	NGXneW5FVVOR	MkjUTWM2OD1zMDFOwG0>	MWeyN\|g1PDB\|OB?=
T-84	M{O0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXsc3IyOCEQvF2=	MnPzO\|IhcA>?	MkewSG1UVw>?	NF\VSnFKSzVyPUGwJO69VQ>?	MnzCNlM5PDRyM{i=
NCI-H460	NXfyXGtsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFraSVUyOCEQvF2=	MkKyO\|IhcA>?	NHXV[2lFVVOR	NIS3W4pKSzVyPUGwJO69VQ>?	MXqyN\|g1PDB\|OB?=
Calu-6	M4r2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;JNVAh\|ryP	Ml3UO\|IhcA>?	NFnCU5ZFVVOR	NYDmXlhVUUN3ME2xNEDPxE1?	MWWyN\|g1PDB\|OB?=
HCC-2998	Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXwSGcyOCEQvF2=	M3ns[lczKGh?	NXPYSINRTE2VTx?=	MnLNTWM2OD1zMDFOwG0>	MV2yN\|g1PDB\|OB?=
LS1034	MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{L2bVExKM7:TR?=	NXLZZpk4PzJiaB?=	Mlj0SG1UVw>?	MUjJR\|UxRTFyIN88US=>	MVeyN\|g1PDB\|OB?=
CHP-212	MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;TbZkzOTBizszN	MkPwO\|IhcA>?	M2fwcWROW09?	MU\JR\|UxRTFyIN88US=>	NHrFPWgzOzh2NECzPC=>
SK-N-AS	M{Sx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{S4TVExKM7:TR?=	MX63NkBp	NXf2TJE6TE2VTx?=	MY\JR\|UxRTFyIN88US=>	NXHBUZVlOjN6NESwN\|g>
BFTC-905	NWTKSolJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHoSnMyOCEQvF2=	NHy5eXA4OiCq	NIjhbHJFVVOR	MnvDTWM2OD1zMDFOwG0>	NVX6VWNbOjN6NESwN\|g>
HuT78	MnzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHEOmxUOTBizszN	MkTkO\|IhcA>?	NYrrUJZYTE2VTx?=	Mm[1TWM2OD13MjDuUS=>	NEHTeHMzOzh2NECzPC=>
RPMI-8226	NW[5RmpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWSxNEDPxE1?	M3TNSFczKGh?	NEn5UFhFVVOR	MW\JR\|UxRTJ4MzDuUS=>	MYGyN\|g1PDB\|OB?=
BC-3	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV6xNEDPxE1?	MUS3NkBp	MVnEUXNQ	MYHJR\|UxRTJ5NzDuUS=>	MV2yN\|g1PDB\|OB?=
ACHN	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorJNVAh\|ryP	MmqxO\|IhcA>?	Mo\ySG1UVw>?	NF3tZZdKSzVyPUK5OEBvVQ>?	M2nrOFI{QDR2MEO4
JRT3-T35	M2HKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PMfVExKM7:TR?=	MVO3NkBp	NFL0[JlFVVOR	MX3JR\|UxRTJ7NTDuUS=>	MmHINlM5PDRyM{i=
SK-MES-1	NGjTTFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjMW2FPOTBizszN	MVO3NkBp	NInNWJlFVVOR	MXfJR\|UxRTN{OTDuUS=>	NUjQ[mJKOjN6NESwN\|g>
CESS	Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17PT\|ExKM7:TR?=	NEjrOIs4OiCq	NYLmXG93TE2VTx?=	MkHMTWM2OD12OUegcm0>	MmDDNlM5PDRyM{i=
H4	NXrSUoRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoT5NVAh\|ryP	MV63NkBp	MlLrSG1UVw>?	NFS2NZNKSzVyPU[xPUBvVQ>?	M3PBOFI{QDR2MEO4
BC-1	M4\rOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTUNVAh\|ryP	NFnFWGY4OiCq	NIroS3BFVVOR	NHXDeWNKSzVyPUewOEBvVQ>?	MlK3NlM5PDRyM{i=
DB	NIrXSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPrbIQyOCEQvF2=	NUHvVIFXPzJiaB?=	NVHHSXpQTE2VTx?=	NYDKS3RjUUN3ME24O\|Mhdk1?	NWnNXYdGOjN6NESwN\|g>
RPMI-6666	MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDxNVAh\|ryP	MXi3NkBp	NVLUU45MTE2VTx?=	M2O0cGlEPTB;OUK4JI5O	MX:yN\|g1PDB\|OB?=
MC/CAR	MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PsTFExKM7:TR?=	NVzvN285PzJiaB?=	MYXEUXNQ	MnvNTWM2OD1zLkCwNkDPxE1?	MVGyN\|g1PDB\|OB?=
SNU-1	NYrIfWhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2T5V\|ExKM7:TR?=	MmX6O\|IhcA>?	NWK0WYpbTE2VTx?=	MXjJR\|UxRTFwNUCxJO69VQ>?	M{\Se\|I{QDR2MEO4
CEM/C1	M2HmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXpNVAh\|ryP	Mly5O\|IhcA>?	M1H4fWROW09?	MXLJR\|UxRTFwN{ezJO69VQ>?	M3fX[FI{QDR2MEO4
GDM-1	NWT3T5NIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTDZ\|cyOCEQvF2=	M1rGclczKGh?	MWDEUXNQ	NVfIN5k3UUN3ME2xMlk6PyEQvF2=	MX[yN\|g1PDB\|OB?=
HT-1080	NIPvXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml2wNVAh\|ryP	MVm3NkBp	M3vGWGROW09?	MkPCTWM2OD1{LkCwOEDPxE1?	MkL2NlM5PDRyM{i=
HL-60	M{SwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVKxNEDPxE1?	M1PYc\|czKGh?	MV;EUXNQ	MU\JR\|UxRTJwMUe4JO69VQ>?	NU\wRo5VOjN6NESwN\|g>
C3A	NX\WSYxrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWT4SmF4OTBizszN	NVvr[25iPzJiaB?=	M{TsPWROW09?	NELkcVFKSzVyPUWuOFE1KM7:TR?=	NULoOGwzOjN6NESwN\|g>
MES-SA	NXvFe282T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLVTWFQOTBizszN	NWHPNHpCPzJiaB?=	M3XReGROW09?	M2rES2lEPTB;Nj65PFkh\|ryP	MXGyN\|g1PDB\|OB?=
22Rv1	Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGf2VoYyOCEQvF2=	NIO1O2c4OiCq	NIDSbWJFVVOR	NFTKeZRKSzVyPUGwJO69VQ>?	Ml\aNlM5PDRyM{i=
647-V	MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4WzbVExKM7:TR?=	MXK3NkBp	MmfjSG1UVw>?	M1LWOmlEPTB;MUCg{txO	M4LRTFI{QDR2MEO4
786-O	NUXjcohlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILZO2oyOCEQvF2=	M3XvV\|czKGh?	MU\EUXNQ	M3LUUGlEPTB;MUCg{txO	NYnjdo5HOjN6NESwN\|g>
A172	Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\vbVExKM7:TR?=	NGrO[XQ4OiCq	M1m1PGROW09?	NVniUXA2UUN3ME2xNEDPxE1?	NVTIeXU4OjN6NESwN\|g>
A204	NY\iUm41T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml[4NVAh\|ryP	NV[xU5A4PzJiaB?=	MUXEUXNQ	MmHpTWM2OD1zMDFOwG0>	NU[1PItCOjN6NESwN\|g>
A427	MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37kclExKM7:TR?=	MmDWO\|IhcA>?	NWfD[FE2TE2VTx?=	NXvSOJV1UUN3ME2xNEDPxE1?	MWOyN\|g1PDB\|OB?=
A431	NUnTOJZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TNclExKM7:TR?=	M2DZcVczKGh?	NIDFbHhFVVOR	MnXsTWM2OD1zMDFOwG0>	MWWyN\|g1PDB\|OB?=
A2780	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELoVW4yOCEQvF2=	NUPtOmpuPzJiaB?=	MnHkSG1UVw>?	MnjwTWM2OD1zMDFOwG0>	MWSyN\|g1PDB\|OB?=
ARH-77	NGqzNWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPJe4YyOCEQvF2=	NIi3eZY4OiCq	NEDxdW9FVVOR	NXrMS21FUUN3ME2xNEDPxE1?	MVKyN\|g1PDB\|OB?=
Be(2)C	M3r4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUL4ZYE{OTBizszN	M4H2OVczKGh?	NG\2O5hFVVOR	NHHrZWJKSzVyPUGwJO69VQ>?	MXyyN\|g1PDB\|OB?=
BT-20	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjEUJpQOTBizszN	M3njNVczKGh?	NWCzWWRlTE2VTx?=	Mn3iTWM2OD1zMDFOwG0>	MlS3NlM5PDRyM{i=
BxPc3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mli4NVAh\|ryP	M3rKUVczKGh?	MWjEUXNQ	MnXETWM2OD1zMDFOwG0>	MoDWNlM5PDRyM{i=
C-4 I	NHS0fHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPuRm1VOTBizszN	MV[3NkBp	NIGwfFZFVVOR	NF\XdlFKSzVyPUGwJO69VQ>?	NGjSUW0zOzh2NECzPC=>
C33A	MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4[xV\|ExKM7:TR?=	MVK3NkBp	NFrk[XVFVVOR	NEnxOJBKSzVyPUGwJO69VQ>?	M3W5PVI{QDR2MEO4
CAL-27	Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHZNVAh\|ryP	MofPO\|IhcA>?	Ml\SSG1UVw>?	NIrIOGJKSzVyPUGwJO69VQ>?	M4DFS\|I{QDR2MEO4
CAL-62	MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmf4NVAh\|ryP	MVe3NkBp	MmnuSG1UVw>?	MoHTTWM2OD1zMDFOwG0>	NWj6Xm42OjN6NESwN\|g>
Calu-3	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLFfYYyOCEQvF2=	NHHSU\|c4OiCq	NYXrN45mTE2VTx?=	M4\DemlEPTB;MUCg{txO	MYiyN\|g1PDB\|OB?=
CaOV3	NIHrTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfoe5VzOTBizszN	MlnUO\|IhcA>?	MnftSG1UVw>?	M2DicmlEPTB;MUCg{txO	M4XGfFI{QDR2MEO4
CGTHW1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3DNVAh\|ryP	M4C3ZlczKGh?	NH21bndFVVOR	NXrmfVlrUUN3ME2xNEDPxE1?	NGPZ[3MzOzh2NECzPC=>
CHL-1	NHLXUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVOxNEDPxE1?	NVPVVVVjPzJiaB?=	MlfiSG1UVw>?	M2P3eGlEPTB;MUCg{txO	Mn3pNlM5PDRyM{i=
Colo320DM	Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfFPXoyOCEQvF2=	M1\NV\|czKGh?	NELCOlVFVVOR	MWLJR\|UxRTFyIN88US=>	NH7Q[o8zOzh2NECzPC=>
Colo704	NWrLUHYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXOxNEDPxE1?	MUW3NkBp	MU\EUXNQ	NXnn[od3UUN3ME2xNEDPxE1?	NXT5SnhnOjN6NESwN\|g>
COR-L23	MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLo[lc2OTBizszN	M17FNlczKGh?	NVzyNJNXTE2VTx?=	NVvXdmV5UUN3ME2xNEDPxE1?	MnPmNlM5PDRyM{i=
CRO-AP2	NYC4RY5ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVmxNEDPxE1?	MWW3NkBp	NXWwNlliTE2VTx?=	NYTC[oIyUUN3ME2xNEDPxE1?	M37vZVI{QDR2MEO4
Daudi	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYixNEDPxE1?	MkD5O\|IhcA>?	MYDEUXNQ	M3GxZmlEPTB;MUCg{txO	MYSyN\|g1PDB\|OB?=
DOTC 24510	NVewS\|BET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUmxNEDPxE1?	M33NbVczKGh?	NHH0N\|hFVVOR	MYnJR\|UxRTFyIN88US=>	M4LjV\|I{QDR2MEO4
DU-145	MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXGxNEDPxE1?	M2riZVczKGh?	MnzESG1UVw>?	MVjJR\|UxRTFyIN88US=>	NE[5NoszOzh2NECzPC=>
EB-3	NHrONlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjjV3JyOTBizszN	MnTjO\|IhcA>?	NWLWdHo{TE2VTx?=	MYDJR\|UxRTFyIN88US=>	M3HZOVI{QDR2MEO4
EFM-19	M3HJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUOxNEDPxE1?	M3rsRlczKGh?	NFzuWWpFVVOR	NImyXJRKSzVyPUGwJO69VQ>?	MWWyN\|g1PDB\|OB?=
EKVX	NYfSTlZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofmNVAh\|ryP	M1jPcVczKGh?	M3TTZWROW09?	M3\hO2lEPTB;MUCg{txO	NH2xTnYzOzh2NECzPC=>
FaDu	MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXexNEDPxE1?	NXnj[W5sPzJiaB?=	MWjEUXNQ	MlTnTWM2OD1zMDFOwG0>	Mon3NlM5PDRyM{i=
G401	M{CzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;L[m8yOCEQvF2=	NXy2R2xMPzJiaB?=	M4rYOmROW09?	M1;0WGlEPTB;MUCg{txO	NFjCclEzOzh2NECzPC=>
HCC-70	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHX[mIyOCEQvF2=	NGPSToc4OiCq	NXzteVdbTE2VTx?=	M{X5R2lEPTB;MUCg{txO	NFHZOJkzOzh2NECzPC=>
HCC-1954	NIfq[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17XblExKM7:TR?=	NVfvZnFKPzJiaB?=	M1fGWGROW09?	MlLOTWM2OD1zMDFOwG0>	M1vpZ\|I{QDR2MEO4
Hela	MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4m4ZVExKM7:TR?=	NEHabGk4OiCq	MVTEUXNQ	M3P4XGlEPTB;MUCg{txO	NFvQbHozOzh2NECzPC=>
Hep3B	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXmxNEDPxE1?	M4TV[lczKGh?	Mn3NSG1UVw>?	M3\EVmlEPTB;MUCg{txO	MnL5NlM5PDRyM{i=
HMCB	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX6xNEDPxE1?	MVe3NkBp	NX7OeYVwTE2VTx?=	MnfVTWM2OD1zMDFOwG0>	MWOyN\|g1PDB\|OB?=
HN5	M3;Wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHnR4gyOCEQvF2=	M2K5O\|czKGh?	M2nYSWROW09?	NIHnRZlKSzVyPUGwJO69VQ>?	MXKyN\|g1PDB\|OB?=
HOS	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHkN3VzOTBizszN	MYS3NkBp	NYrZend4TE2VTx?=	M4\5UmlEPTB;MUCg{txO	MYWyN\|g1PDB\|OB?=
HPAF-II	NHnKenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvKNVAh\|ryP	MWS3NkBp	NUDsO3UyTE2VTx?=	NFvWXHZKSzVyPUGwJO69VQ>?	MUSyN\|g1PDB\|OB?=
Hs746.T	M1rXZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUi5V25QOTBizszN	NETPfpU4OiCq	MnziSG1UVw>?	M4fxPGlEPTB;MUCg{txO	MYGyN\|g1PDB\|OB?=
HT	NX\r[otHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XOcVExKM7:TR?=	NHPBcIE4OiCq	NXv0SllWTE2VTx?=	MWfJR\|UxRTFyIN88US=>	MYOyN\|g1PDB\|OB?=
HT-3	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XSclExKM7:TR?=	NUTjSZVmPzJiaB?=	NXfSZYs1TE2VTx?=	NYezeZdWUUN3ME2xNEDPxE1?	M4XxNFI{QDR2MEO4
HuNS-1	NXrZcFl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlKwNVAh\|ryP	Mn3OO\|IhcA>?	NXnxW5BDTE2VTx?=	M2P1VmlEPTB;MUCg{txO	NF7iVnEzOzh2NECzPC=>
IGROV1	NY\vS\|dpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX[yPJozOTBizszN	M1;JSFczKGh?	MmrYSG1UVw>?	NEHiOYNKSzVyPUGwJO69VQ>?	NY\tRphqOjN6NESwN\|g>
J82	NYHUfIZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofzNVAh\|ryP	MU[3NkBp	MW\EUXNQ	MoTmTWM2OD1zMDFOwG0>	NFzsc4EzOzh2NECzPC=>
JM1	M2j6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TVTFExKM7:TR?=	NIPySY84OiCq	Mk\0SG1UVw>?	MYDJR\|UxRTFyIN88US=>	MlzHNlM5PDRyM{i=
Kato III	NIjXRnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\ONVAh\|ryP	NHHidYU4OiCq	NXjDRoZOTE2VTx?=	MnvyTWM2OD1zMDFOwG0>	M1\ielI{QDR2MEO4
KHOS-240S	NV\pS41sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfPNVAh\|ryP	MYW3NkBp	NWniVmZoTE2VTx?=	M3\kfGlEPTB;MUCg{txO	M3XyO\|I{QDR2MEO4
KM-12	M37Dc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2myblExKM7:TR?=	M4XtSFczKGh?	NWHYVppVTE2VTx?=	MWTJR\|UxRTFyIN88US=>	NGfl[ZQzOzh2NECzPC=>
KPL-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWOw[m4{OTBizszN	MYO3NkBp	Ml7ZSG1UVw>?	NFTSUmZKSzVyPUGwJO69VQ>?	Mo\VNlM5PDRyM{i=
KYSE-30	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PZW\|ExKM7:TR?=	NFHHeWw4OiCq	MUfEUXNQ	MYfJR\|UxRTFyIN88US=>	NY[0cFRsOjN6NESwN\|g>
LNCaP	Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnaT25{OTBizszN	NX7rbIVVPzJiaB?=	M3;ZU2ROW09?	MkDITWM2OD1zMDFOwG0>	NHzVOnEzOzh2NECzPC=>
MCF-7	M4jqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTjUJQyOCEQvF2=	Mni1O\|IhcA>?	MXfEUXNQ	M2\Fd2lEPTB;MUCg{txO	NFfzUIwzOzh2NECzPC=>
MC-IXC	M3jFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYGxNEDPxE1?	NXPYR4ZUPzJiaB?=	MUHEUXNQ	M1fMc2lEPTB;MUCg{txO	MYGyN\|g1PDB\|OB?=
MDA-MB-175 VII	MoPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUSxNEDPxE1?	NFPzUJo4OiCq	MX\EUXNQ	NEL2bXhKSzVyPUGwJO69VQ>?	NWHNOlNqOjN6NESwN\|g>
MDA-MB-468	Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV24dGg2OTBizszN	NVTIell2PzJiaB?=	Mn;aSG1UVw>?	M4fzc2lEPTB;MUCg{txO	NFj6bI8zOzh2NECzPC=>
MiaPaCa	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HIZVExKM7:TR?=	M{PpfFczKGh?	MmSySG1UVw>?	MkDvTWM2OD1zMDFOwG0>	MmHGNlM5PDRyM{i=
Molt-4	NEfCPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXr6e\|JNOTBizszN	MkTsO\|IhcA>?	NFq4e3NFVVOR	M1jpbmlEPTB;MUCg{txO	MlHENlM5PDRyM{i=
NCI-ADR/RES	NIPvS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\ReZkyOCEQvF2=	M3zidVczKGh?	MYfEUXNQ	NGHCelFKSzVyPUGwJO69VQ>?	NGnMNXMzOzh2NECzPC=>
NCI-H69	MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\zWYgyOCEQvF2=	NHG1XXE4OiCq	NHrxcnlFVVOR	M3jkeGlEPTB;MUCg{txO	MmjGNlM5PDRyM{i=
NCI-H82	NYTwTYd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrzNVAh\|ryP	NF7IcFU4OiCq	MoDjSG1UVw>?	NH7vSYRKSzVyPUGwJO69VQ>?	NHfkUXkzOzh2NECzPC=>
NCI-N87	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3sVngyOCEQvF2=	NWWwb4kzPzJiaB?=	NEjRTJNFVVOR	M3X5N2lEPTB;MUCg{txO	M{PqPVI{QDR2MEO4
NCI-H146	NHnTNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkK2NVAh\|ryP	NIjSUpg4OiCq	NVXXflVZTE2VTx?=	NYLVUW1RUUN3ME2xNEDPxE1?	MXuyN\|g1PDB\|OB?=
NCI-H157	M4PzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTGNVAh\|ryP	NV3idJBlPzJiaB?=	M13SemROW09?	MX\JR\|UxRTFyIN88US=>	MmfGNlM5PDRyM{i=
NCI-H187	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU[xNEDPxE1?	NIr6UZM4OiCq	Mke4SG1UVw>?	M1fFW2lEPTB;MUCg{txO	MWSyN\|g1PDB\|OB?=
NCI-H209	MmLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M176O\|ExKM7:TR?=	MUS3NkBp	M1qxbWROW09?	Mo\pTWM2OD1zMDFOwG0>	M3H3S\|I{QDR2MEO4
NCI-H226	NHm5VFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\Fb5YyOCEQvF2=	NWDUNoZsPzJiaB?=	MUjEUXNQ	MnOxTWM2OD1zMDFOwG0>	NGHNXoMzOzh2NECzPC=>
NCI-H292	Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHWNVAh\|ryP	NYXz[nB1PzJiaB?=	M4jVVGROW09?	NFTkUoFKSzVyPUGwJO69VQ>?	M4DN[\|I{QDR2MEO4
NCI-H322	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHTPHYyOCEQvF2=	NFL5boM4OiCq	NWLCN4lqTE2VTx?=	MVXJR\|UxRTFyIN88US=>	NXvpWXREOjN6NESwN\|g>
NCI-H358	M2rofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGn4PXoyOCEQvF2=	M1XaWlczKGh?	MkfQSG1UVw>?	NVfOU3JOUUN3ME2xNEDPxE1?	NWTZSXlZOjN6NESwN\|g>
NCI-H520	MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDsNVAh\|ryP	Mnu3O\|IhcA>?	M3vTfmROW09?	NFzvTW1KSzVyPUGwJO69VQ>?	NVu4OXY5OjN6NESwN\|g>
NCI-H526	M1O1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7kN4gyOCEQvF2=	NGe5[Fk4OiCq	NV\ZfW5nTE2VTx?=	MX3JR\|UxRTFyIN88US=>	M12yTFI{QDR2MEO4
NCI-H630	M1TpW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnKzNVAh\|ryP	NEHoXXk4OiCq	MmjvSG1UVw>?	NX\Qc41sUUN3ME2xNEDPxE1?	MVmyN\|g1PDB\|OB?=
NCI-H661	NGjWepNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYOxNEDPxE1?	M4jCelczKGh?	M4\OSmROW09?	MmnDTWM2OD1zMDFOwG0>	MlS3NlM5PDRyM{i=
NCI-H716	M2\Yfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrTNVAh\|ryP	NXzt[WI4PzJiaB?=	NX3Qdo5LTE2VTx?=	MWfJR\|UxRTFyIN88US=>	Mn[xNlM5PDRyM{i=
NCI-H1563	M{TFXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\pZVExKM7:TR?=	NE\HUlk4OiCq	NVniOFlbTE2VTx?=	MXPJR\|UxRTFyIN88US=>	MYOyN\|g1PDB\|OB?=
NCI-H1792	Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUn1Xos3OTBizszN	M{LMdlczKGh?	NEDyPIhFVVOR	NYKzemh2UUN3ME2xNEDPxE1?	MojaNlM5PDRyM{i=
NCI-H2030	M4XMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofTNVAh\|ryP	MX[3NkBp	MV\EUXNQ	MXzJR\|UxRTFyIN88US=>	NGX6eXczOzh2NECzPC=>
NCI-H2052	MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX:2ZndKOTBizszN	MWS3NkBp	NUKxTYo5TE2VTx?=	NXvMeYRlUUN3ME2xNEDPxE1?	MVqyN\|g1PDB\|OB?=
NCI-H2122	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELVUHoyOCEQvF2=	M4fIb\|czKGh?	Mn\PSG1UVw>?	NV;jd201UUN3ME2xNEDPxE1?	NUjjXIpkOjN6NESwN\|g>
NCI-H2228	MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYKxNEDPxE1?	M1HUZ\|czKGh?	NETCfpJFVVOR	NVnrNlBZUUN3ME2xNEDPxE1?	MUSyN\|g1PDB\|OB?=
OE-19	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYSxNEDPxE1?	MXi3NkBp	NEe1RmFFVVOR	NUjoUpVbUUN3ME2xNEDPxE1?	M4K2SFI{QDR2MEO4
OE-21	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDMOYg5OTBizszN	MYi3NkBp	NEHKTpNFVVOR	NYnIWZJkUUN3ME2xNEDPxE1?	NYqzSHN4OjN6NESwN\|g>
OE-33	NVm3eYVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnrfW82OTBizszN	MWm3NkBp	NHTq[Y5FVVOR	MXLJR\|UxRTFyIN88US=>	M{W3RlI{QDR2MEO4
OVCAR-3	NGPzcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTiNVAh\|ryP	M3\pVVczKGh?	NIfRSVRFVVOR	NIHHdotKSzVyPUGwJO69VQ>?	Mn[wNlM5PDRyM{i=
OVCAR-4	NHTkdXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTONVAh\|ryP	Ml\SO\|IhcA>?	MlHySG1UVw>?	MVPJR\|UxRTFyIN88US=>	MWqyN\|g1PDB\|OB?=
OVCAR-5	M1\wdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHVNVAh\|ryP	MV[3NkBp	M3rNb2ROW09?	NVuzXGxPUUN3ME2xNEDPxE1?	MljGNlM5PDRyM{i=
P3HR-1	MkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3xeZQyOCEQvF2=	MlvvO\|IhcA>?	M{DMW2ROW09?	NYCyV4trUUN3ME2xNEDPxE1?	M{TOWVI{QDR2MEO4
PC-3	NVfaeYExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\Q[Xc2OTBizszN	MortO\|IhcA>?	NVHqUGJ3TE2VTx?=	M2XKe2lEPTB;MUCg{txO	NV\PdI9MOjN6NESwN\|g>
Raji	NELmO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkmxNVAh\|ryP	M1rDOVczKGh?	NFz5U4RFVVOR	MnPGTWM2OD1zMDFOwG0>	MUWyN\|g1PDB\|OB?=
RD	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2D6XFExKM7:TR?=	M2T1dlczKGh?	M1;CXmROW09?	Mo[yTWM2OD1zMDFOwG0>	NEX6cmkzOzh2NECzPC=>
RD-ES	NGTRNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX:xNEDPxE1?	NH[xTnI4OiCq	MnrBSG1UVw>?	NUC4UpMxUUN3ME2xNEDPxE1?	MWKyN\|g1PDB\|OB?=
RL	M3PXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWKzepRmOTBizszN	NXnTfoZzPzJiaB?=	MUPEUXNQ	Mn3ZTWM2OD1zMDFOwG0>	MnzmNlM5PDRyM{i=
SaOS2	M3v5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDyUWEyOCEQvF2=	NFfJO2o4OiCq	NGLjclVFVVOR	MV7JR\|UxRTFyIN88US=>	MlL4NlM5PDRyM{i=
SCC-9	MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jLR\|ExKM7:TR?=	MmfvO\|IhcA>?	M4XL[GROW09?	MljzTWM2OD1zMDFOwG0>	MljINlM5PDRyM{i=
SCC-12	M{m1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXMOVUyOCEQvF2=	MV:3NkBp	MojMSG1UVw>?	NX3E[IdLUUN3ME2xNEDPxE1?	MnzqNlM5PDRyM{i=
SCC-13	M{PlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mle5NVAh\|ryP	M{TsUVczKGh?	MnjKSG1UVw>?	NG\iR4lKSzVyPUGwJO69VQ>?	M1LKRVI{QDR2MEO4
SCC-15	M4DIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nkUVExKM7:TR?=	NFjrVGE4OiCq	M1z0bGROW09?	Mn;VTWM2OD1zMDFOwG0>	M1O2WlI{QDR2MEO4
SCC-25	Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHlOGhOOTBizszN	M{LTNFczKGh?	NIS5U\|NFVVOR	MoHITWM2OD1zMDFOwG0>	NWPGe\|E4OjN6NESwN\|g>
SCLC-3	MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfQO5cyOCEQvF2=	NV7mT\|F5PzJiaB?=	MmPFSG1UVw>?	NHzIZo9KSzVyPUGwJO69VQ>?	NX2wSlFyOjN6NESwN\|g>
SF-268	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXmwOWwyOTBizszN	M3PPNVczKGh?	MljuSG1UVw>?	NUXnOY9SUUN3ME2xNEDPxE1?	MV:yN\|g1PDB\|OB?=
SF-295	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{X6d\|ExKM7:TR?=	M2rLRVczKGh?	NYLUdnVvTE2VTx?=	MYXJR\|UxRTFyIN88US=>	NETybFkzOzh2NECzPC=>
SJRH30	MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHQTGtHOTBizszN	MX[3NkBp	NUmybIdLTE2VTx?=	NXuxXYtqUUN3ME2xNEDPxE1?	Mom3NlM5PDRyM{i=
SK-BR-3	MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUOxNEDPxE1?	NVXSTXRtPzJiaB?=	NIToUYNFVVOR	MX;JR\|UxRTFyIN88US=>	MV2yN\|g1PDB\|OB?=
SK-LMS-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGr5PXEyOCEQvF2=	NIDkSFI4OiCq	Mn2zSG1UVw>?	MkTJTWM2OD1zMDFOwG0>	MljMNlM5PDRyM{i=
SK-N-DZ	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\jU4cyOCEQvF2=	MWi3NkBp	M4\N[GROW09?	M{HNfGlEPTB;MUCg{txO	MoLkNlM5PDRyM{i=
SK-N-F1	M{PJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWmxNEDPxE1?	NE\nZWU4OiCq	NFjaU2VFVVOR	MoPQTWM2OD1zMDFOwG0>	NH;kZ3AzOzh2NECzPC=>
SKOV-3	NHrrWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTo[YhLOTBizszN	MXy3NkBp	NWn5UnAxTE2VTx?=	NYPHdIh1UUN3ME2xNEDPxE1?	M4rPNFI{QDR2MEO4
SK-UT-1	NGfFT\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXqxNEDPxE1?	MoHXO\|IhcA>?	MWfEUXNQ	NWDw[GlFUUN3ME2xNEDPxE1?	Mk\QNlM5PDRyM{i=
SN12C	NETWUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUCxNEDPxE1?	NHL2W284OiCq	NU\PN4xCTE2VTx?=	MYPJR\|UxRTFyIN88US=>	NVzjUI1POjN6NESwN\|g>
SNB-19	NVnIT5lJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPrd\|ZWOTBizszN	MVS3NkBp	M4XUc2ROW09?	MoTpTWM2OD1zMDFOwG0>	NYXIcmg3OjN6NESwN\|g>
SNU-5	MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWGxNEDPxE1?	NWjT[IFXPzJiaB?=	NGrpbVZFVVOR	NGDtcHBKSzVyPUGwJO69VQ>?	NGjTbFczOzh2NECzPC=>
SNU-16	NVW2[25ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV2xNEDPxE1?	MkH3O\|IhcA>?	MYLEUXNQ	NXrFXldSUUN3ME2xNEDPxE1?	M{LwTVI{QDR2MEO4
SNU-398	MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHVO4hOOTBizszN	NV\KSJFYPzJiaB?=	MWHEUXNQ	MVPJR\|UxRTFyIN88US=>	MlH1NlM5PDRyM{i=
SNU-449	M1HXRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXOxNEDPxE1?	MnqzO\|IhcA>?	M2nO[WROW09?	NF\yXW9KSzVyPUGwJO69VQ>?	MoXjNlM5PDRyM{i=
SR	M{e4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHqTYJMOTBizszN	MV23NkBp	M3nzRmROW09?	NGjwcldKSzVyPUGwJO69VQ>?	NIn3UJUzOzh2NECzPC=>
ST486	NXPJdIZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\RWIMyOCEQvF2=	NHy4XJE4OiCq	NXjOWIFiTE2VTx?=	NFrGXHZKSzVyPUGwJO69VQ>?	MnzKNlM5PDRyM{i=
SW579	Mnf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjaUnkyOCEQvF2=	MonCO\|IhcA>?	NEXGcldFVVOR	MYTJR\|UxRTFyIN88US=>	MlroNlM5PDRyM{i=
SW684	M2Pn[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIOyNmgyOCEQvF2=	NF2xXoQ4OiCq	MYXEUXNQ	M1;iVmlEPTB;MUCg{txO	M2[wdFI{QDR2MEO4
SW-780	NUDsb\|VNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moj1NVAh\|ryP	NITpV4Q4OiCq	Mk\YSG1UVw>?	MoT3TWM2OD1zMDFOwG0>	NWXlTmM5OjN6NESwN\|g>
SW900	M{DmeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfwNpp5OTBizszN	NUPC[HNQPzJiaB?=	NUL2eZdQTE2VTx?=	NVHyZ481UUN3ME2xNEDPxE1?	Mn3WNlM5PDRyM{i=
SW1088	NXTqOI9GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nWS\|ExKM7:TR?=	NEDrUmM4OiCq	MV3EUXNQ	MWPJR\|UxRTFyIN88US=>	MoPhNlM5PDRyM{i=
SW1463	NHrySIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETHe5AyOCEQvF2=	NULnR4tuPzJiaB?=	NGq0WJVFVVOR	MWLJR\|UxRTFyIN88US=>	NGn1VmQzOzh2NECzPC=>
SW1990	NUOx[oZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWOxNEDPxE1?	M4j4bVczKGh?	MVnEUXNQ	NVTzWHh4UUN3ME2xNEDPxE1?	M3jVdVI{QDR2MEO4
T47D	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{S5RVExKM7:TR?=	MWG3NkBp	NITTV3dFVVOR	MXnJR\|UxRTFyIN88US=>	M{Hhb\|I{QDR2MEO4
TE381.T	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYWxNEDPxE1?	M2TPUVczKGh?	MmrzSG1UVw>?	MWDJR\|UxRTFyIN88US=>	MYGyN\|g1PDB\|OB?=
TK-10	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlSzNVAh\|ryP	NELOXpo4OiCq	M4r1WWROW09?	M{m2N2lEPTB;MUCg{txO	NEizWZAzOzh2NECzPC=>
U2OS	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nVd\|ExKM7:TR?=	NU\ydJFKPzJiaB?=	MWDEUXNQ	MoC2TWM2OD1zMDFOwG0>	NVy1RZFrOjN6NESwN\|g>
U251	NVXI[5F2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LUcFExKM7:TR?=	M1nrNVczKGh?	NV3kZnF6TE2VTx?=	M1zrXmlEPTB;MUCg{txO	NEPqXoEzOzh2NECzPC=>
UACC-812	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXXNVAh\|ryP	MYm3NkBp	MmPrSG1UVw>?	M3LtWmlEPTB;MUCg{txO	MYKyN\|g1PDB\|OB?=
YAPC	M2jVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUmxNEDPxE1?	M32xbVczKGh?	Mk\ZSG1UVw>?	MlfRTWM2OD1zMDFOwG0>	NYXtWnkyOjN6NESwN\|g>
ZR-75-1	NIPLWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zDUFExKM7:TR?=	M2PQeVczKGh?	MVnEUXNQ	M1WzSGlEPTB;MUCg{txO	MoW0NlM5PDRyM{i=
A375	NULZT2JvTnWwY4Tpc44h[XO\|YYm=	MXGxMlIh\|ryP	Mlf4OEBp	MW\EUXNQ	NVzXT\|Y1UW6qaXLpeIlwdiCxZjDwbI9{eGixconsZZRqd25ib3[gUWVMNCCHUlusJIFv\CCVNmC=	M{PBPFIzOzh7NEex
YUSIT1	MWrGeY5kfGmxbjDhd5NigQ>?			NYnpWpV[TE2VTx?=	NYLHXmZoemWmdXPl[EB{\W6\|aYTpeol1gSC5aYToJGlEPTBiPjCwMlUh\|ryP	MXiyNlM5QTR5MR?=
MeWo	NUPyRVQ6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NFTKZ4lFVVOR	MWrJR\|UxKD1iOUi3JI5O	M4DxdlI3ODF6NUK0
WiDr	MluxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NITVRoFFVVOR	NX3kZWNvUUN3MDC9JFc3KG6P	NHHpbpEzPjBzOEWyOC=>
Colo-205	M2OxeGZ2dmO2aX;uJIF{e2G7	NFn5U\|cyKM7:TR?=	MYW0JIQ>	NWPPbGV6TE2VTx?=	NXnNOoRQUW6mdXPl[EBiKGirZ3jsfUBkd22yYYLhZoxmKGOxbYDhZ5Rqd25icHjlco91gXCn	NVz6Nm9jOjV\|OEGxOVI>
RBW-1	M2PGTmZ2dmO2aX;uJIF{e2G7	NEjocFEyKM7:TR?=		NICyUllFVVOR	NEK2VWxPdyC{ZXT1Z5Rqd25ib3[gUYVsKDFxMjDwbI9{eGixconsZZRqd25?	NXfyNGFSOjR6OEW2PVA>
RBO-1	NHuxPHRHfW6ldHnvckBie3OjeR?=	NEfkfFMyKM7:TR?=		MnnzSG1UVw>?	M1TJcmlvcGmkaYTpc44hd2ZiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44>	NETmPXEzPDh6NU[5NC=>
RBO-2	M37mXmZ2dmO2aX;uJIF{e2G7	M3TGXlEh\|ryP		M2jzNmROW09?	NEH6RXhKdmirYnn0bY9vKG:oIDDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>?	M4fVT\|I1QDh3Nkmw
RBOW	M3f2bWZ2dmO2aX;uJIF{e2G7	NFrKTIQyKM7:TR?=		NYPYOFlrTE2VTx?=	MlL3TY5pcWKrdHnvckBw\iBiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44>	Mn[xNlQ5QDV4OUC=
M257	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TCZlExOCCwTR?=	Mom3O\|IhcA>?		MWjEc4V{KG6xdDDpcohq[mm2IIDyc4xq\mW{YYTpc44hd2ZiTUK1O{Bk\WyuIHjhdoJwfXKrbnege4lt\CC2eYDlJGJTSUZ?	NHjidIgzOzNzN{S0Oi=>
LCP	NGn5NFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTaNVAxKG6P	NEjFOmY4OiCq		NID1flJKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44hd2ZiTFPQJINmdGxiaHHyZo92emmwZzDCVmFHKFZ4MEDSJI12fGGwdHH0bY9v	MlXXNlM{OTd2NE[=
WM266	NUnITXYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7iOlNIOTByIH7N	NH7zOWw4OiCq		MnvwTY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKFePMk[2JINmdGxiaHHyZo92emmwZzDCVmFHKFZ4MEHEJI12fGGwdHH0bY9v	MnjENlM{OTd2NE[=
M257	Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vFXFExOCCwTR?=	NInKUJE4OiCq		NXnQWYk1TG:nczDuc5QhcW6qaXLpeEBGWktzLUKgdIhwe3Cqb4L5cIF1cW:wIHnuJG0zPTdiY3XscEBp[XKkb4XybY5oKHerbHSgeJlx\SCEUlHG	NE[3bXgzOzNzN{S0Oi=>
LCP	NHLDZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{j3XVExOCCwTR?=	NVracFh5PzJiaB?=		M3e1dmlvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDMR3Ah[2WubDDoZZJjd3W{aX7nJGJTSUZiVk[wNHIhdXW2YX70ZZRqd25?	NXn0TFJ4OjN\|MUe0OFY>
WM266	NEG4S4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HFVFExOCCwTR?=	NYi0OlM6PzJiaB?=		NYe5VGFDUW6qaXLpeEBGWktzLUKgdIhwe3Cqb4L5cIF1cW:wIHnuJHdOOjZ4IHPlcIwhcGG{Yn;1dolv\yCEUlHGJHY3ODCGIH31eIFvfGG2aX;u	MoGyNlM{OTd2NE[=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pMEK / pERK / ERK; PubMed: 31158244 PLoS One Cell lines as shown were treated with dabrafenib, over a dose range, for 1 hour. UT = untransfected. Expression and/or phosphorylation of the indicated proteins were assessed by immunoblot. p-S6 / p-AKT308 / p-AKT473; PubMed: 24735930 Mol Cancer Western blot analysis of phosphorylated proteins in MAPK and the PI3K-AKT pathway after 24 hours exposure to increasing concentrations of dabrafenib. β-catenin; PubMed: 29167314 Mol Cancer Ther HT-29 cells were treated with BRAF inhibitors Dabrafenib (2 μM), GDC-0879 (4 μM) or Vemurafenib (2 μM) for indicated times. The whole cell lysates were used for western blot with indicated antibodies.	31158244 24735930 29167314
Growth inhibition assay	IC50; PubMed: 24735930 Mol Cancer A panel of 23 BRAF(V600) mutant human melanoma cell lines was treated with serial dilutions (1-10,000 nM) of dabrafenib (A) for 72-120 hours to assess cell viability. The bars represent the average IC50 value of two or more independent experiments in duplicates and the error bars represent the SEM.	24735930

In vivo

Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. ^[1]

Protocol

References

Solubility (25°C)

In vitro	DMSO	30 mg/mL (57.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+45% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dabrafenib (GSK2118436) SDF

Molecular Weight	519.56
Formula	C₂₃H₂₀F₃N₅O₂S₂
CAS No.	1195765-45-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(F)C(=CC=C3)N[S](=O)(=O)C4=C(F)C=CC=C4F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04059224	Recruiting	Drug: Trametinib\|Drug: Dabrafenib	Stage IV Melanoma\|Stage III Melanoma	Universitair Ziekenhuis Brussel	January 28 2019	Phase 2
NCT03668431	Recruiting	Drug: Dabrafenib\|Drug: Trametinib\|Drug: PDR001	Metastatic Colorectal Cancer	Massachusetts General Hospital\|Novartis\|Stand Up To Cancer	October 15 2018	Phase 2
NCT03553329	Completed	Drug: dabrafenib	Unresecable Stage IIIc or IV Melanoma	Poitiers University Hospital	June 2 2018	--
NCT03593993	Recruiting	Procedure: Surgical Cohort	Glioma\|BRAF V600E\|Pleomorphic Xantho-Astrocytoma\|Glioblastoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Musella Foundation	May 19 2018	--
NCT03340506	Recruiting	Drug: dabrafenib\|Drug: trametinib	Melanoma\|Non Small Cell Lung Cancer\|Solid Tumor\|Rare Cancers\|High Grade Glioma	Novartis Pharmaceuticals\|Novartis	December 28 2017	Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Pan Raf Inhibitor

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA-approved Raf Inhibitor

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
Newest Raf Inhibitor

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

Related Raf Products

LY3009120 ^New

LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.
Ravoxertinib (GDC-0994) ^New

GDC-0994 is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Ulixertinib (BVD-523) ^New

Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
Vemurafenib (PLX4032)

Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-Raf^V600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-Raf^V600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold. Vemurafenib (PLX4032, RG7204) induces autophagy.

Features:A novel and potent inhibitor of the B-RAF^V600E oncoprotein.
Sorafenib

Sorafenib is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.

Sorafenib Tosylate

Sorafenib Tosylate is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

PLX-4720

PLX4720 is a potent and selective inhibitor of B-Raf^V600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.

TAK-632

TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.

GDC-0879

GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.

GW5074

GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted.

Choose Your Country or Region

By Signaling Pathways

By product type

Dabrafenib (GSK2118436)